Although thymoglobulin and alemtuzumab are frequently used in hematopoietic stem cell transplantation (HSCT), little is known of their effects on NK cells, which mediate important functions in post-transplantation immunology. In the present study, we determined NK cell death in vitro using propidium iodide and Annexin V. The NK cell activity in 34 patients at day þ 30 after allogeneic HSCT was assessed using the CD107a assay. Alemtuzumab and thymoglobulin were similarly very potent in inducing NK cell death in vitro. Even in low concentrations (o1 lg/ml) the antibodies induced apoptosis and necrosis in a relevant percentage of NK cells (430%). However, the number of tumor reactive (CD107a þ ) NK cells was 13.16 per ll and 1.15 per ll (mean) in patients receiving T-cell depletion with 6 mg/kg thymoglobulin and in patients receiving 100 mg alemtuzumab, respectively (P ¼ 0.02). Although thymoglobulin and alemtuzumab are equally NK cell toxic in vitro, the recovery of NK cell frequency and anti-tumor reactivity is reduced in recipients of alemtuzumab. Our findings can be explained by a longer half-life of alemtuzumab as compared to active thymoglobulin under therapeutic conditions. Prolonged immunosuppression with increased risk of infections and tumor relapse are a potential threat to patients undergoing HCST and receiving alemtuzumab as T-cell depletion.
Introduction
Alemtuzumab (monoclonal anti-CD52) and thymoglobulin (polyclonal rabbit anti-thymocyte globulin (ATG)) are effective in reducing the incidence of GVHD in patients undergoing hematopoietic stem cell transplantation (HSCT). The mechanism of action is depletion of alloreactive T cells in the recipient. This so-called 'in vivo T-cell depletion' is often used in HSCT with a HLA-matched unrelated donor (MUD) as source because acute GVHD occurs more frequent in this setting. 1 During the last decade the use of alemtuzumab and thymoglobulin in patients undergoing HSCT has increased rapidly. 2 Contrasting with the existing knowledge of the effects of alemtuzumab and thymoglobulin on alloreactive T cells, little information is available on their impact on natural killer cells (NK cells), which are the predominant peripheral mononuclear blood cells in the early phase (o90 days) after HSCT. Thus far there is only limited data available describing the effect of in vivo T-cell depletion on the quantitative reconstitution of NK cells after HCST. [3] [4] [5] The impact of T-cell depletion on NK cell function has not yet been investigated, but is of particular interest because the activity of NK cells against recipient tumor cells has been recently described as an important component of the graftversus-tumor (GVT) effect in haploidentical and HLAmismatched HSCT. 6, 7 In the current study, we have investigated the impact of thymoglobulin and alemtuzumab on NK cells in vitro using the propidium iodide (PI) and the Annexin V-FITC Detection Kit for assessing apoptosis and cell death. To determine the influence of thymoglobulin and alemtuzumab in vivo, we assessed the frequency and anti-tumor activity of NK cells in patients with hematological malignancies in the early phase after allogeneic HSCT. For analysis of NK cell function, we used a novel flow cytometry-based assay that detects degranulation of NK cells via surface expression of the lytic granule membrane protein CD107a. 8, 9 Patients and methods Binding of alemtuzumab and thymoglobulin to NK cell surface NK cells were isolated from PBMCs by positive and negative selection of CD56 and CD3 (Micro Beads, Miltenyi Biotech, Bergisch Gladbach, Germany). CD52 expression was assessed by a FITC-labeled m-Ab (Beckman-Coulter, Fichtenhain, Germany). To determine the binding of thymoglobulin, NK cells were incubated with 10 mg/ml thymoglobulin. NK cells were washed and a FITC-labeled secondary anti-rabbit immunoglobulin G (IgG) antibody (Sigma, Munich, Germany) was added according to the recommendations of the manufacturer. To exclude unspecific binding, experiments without thymoglobulin were performed.
Detection of apoptosis and necrosis in vitro by Annexin V staining Apoptosis of NK cells was determined by flow cytometry using the Annexin V-FITC Detection Kit (BeckmanCoulter). All experiments were performed at least three times to assess reproducibility. Reagents were used according to the protocol of the manufacturer and as described previously. 10, 11 In brief, the Annexin V binding test is able to discriminate intact cells (FITCÀ/PIÀ), apoptotic cells (FITC þ /PIÀ) and necrotic cells (FITC þ / PI þ ). NK cells were isolated from PBMCs by positive and negative selection of CD56 and CD3 (Micro Beads, Miltenyi Biotech). Immunomagnetically selected cells (2 Â 10 5 ) were incubated with thymoglobulin or alemtuzmab in concentrations ranging from 0.001 to 1000 mg/ml for 8-72 h. Negative controls were performed without addition of antibodies and with addition of OKT3 (anti-CD3 monoclonal antibody (mAb)) in concentrations ranging from 0.001 to 1000 mg/ml. Positive controls were performed by using 1 mmol solution of daunorubicine. After the incubation period cells were counted to assess loss due to fragmented cells. Cells were stained with 1 ml Annexin V solution and 5 ml propidium iodide solution for flow cytometric analysis. To assess a possible impact of complement-mediated lysis the experiments were performed in duplicate: one series of experiments with RPMI and 10% inactivated human serum and the other series with pooled fresh human serum. Similar results were obtained in both series.
Isolation of peripheral blood mononuclear cells
Peripheral venous blood was stored in heparinized tubes at day þ 30 after allogeneic SCT. PBMC were isolated by density gradient centrifugation on a Ficoll-Paque gradient. The mononuclear cells from the interphase were washed twice in PBS, resuspended and adjusted to 5 Â 10 6 cells per ml in RPMI.
Patients and preparative regimens
Patients with hematological malignancies receiving an allogeneic HSCT were enrolled in our study. Grafts needed to be G-CSF mobilized PBSC from a matched related or MUD containing at least 3 million CD34 þ cells per kg body weight. The study was approved by the Ethics Committee and informed consent was obtained from all patients prior to HSCT. All patients receiving alemtuzumab were participating in a clinical study evaluating the efficacy of donor lymphocyte infusions after day þ 30 post-HSCT. In addition, peripheral blood (PB) of 17 healthy individuals was drawn with informed consent of the donor.
Tumor cell lines
The human cell lines were obtained from German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany): HL60 (ACC3, AML), 12 K562 (ACC10, CML in blast crisis). 13 The cell lines were kept at 37 1C in incubators and supplied with 5% CO 2 and air in cell suspension cultures consisting of RPMI medium supplemented with 4 mmol/l L-glutamine (Sigma, Munich, Germany), 100 U/ ml streptomycin (Sigma), 100 U/ml penicillin (Sigma) and 10%FCS (Kraeber, Wedel, Germany).
CD107a assay
The CD107a assay was performed as described previously. 9 In brief, an effector/target (E/T) ratio of 1:1 (1 Â 10 6 effector cells:1 Â 10 6 target cells in a volume of 400 ml) was used. All experiments were performed using the NK sensitive target cell lines HL60 and K562. HL60 cells have a slightly higher ability to induce degranulation of NK cells compared to K562 cells. 9 In this paper exclusively the results of the experiments with HL60 are shown; however, similar results were obtained when K562 cells were used as targets. To detect unspecific NK cell activation or spontaneous degranulation, tests without target cells were included in every experiment. In each well, containing 400 ml E/T cell suspension, 20 ml of PE-Cy5 or FITCconjugated anti-CD107a mAb was added prior to incubation. PBMCs and target cells were co-incubated (37 1C) for 3 h in total. After the first hour, 10 ml of 2 mM monensin (Sigma, Munich, Germany) in 100% ethanol were added. At the end of co-incubation, cells were washed in PBS and stained with mAb (CD56, CD3 and so on) for flow cytometric analysis. All experiments were done in duplicate to assess reproducibility.
Statistical analysis
Descriptive statistics include absolute and relative frequencies for categorial, mean, standard deviation, median and range for numeric values. Due to the skewed distribution of the variables, the Mann-Whitney U-test or, in case of more than two groups, the Kruskal-Wallis test was applied for confirmatory group comparisons concerning anti-tumor cell activity. The level of significance was 0.05 (two sided). Calculations were performed using commercial (SPSSWIN 12.0) software.
Results

In vitro analysis
Binding of alemtuzumab and thymoglobulin to NK cell surface. In a first step, we assessed the binding capacity of Both antibodies had a strong ability to induce apoptosis in NK cells. Concentrations40.01 mg/ml were needed to induce apoptosis in a relevant proportion of NK cells.
In vivo analysis Patient characteristics and clinical data. PB samples of 34 consecutive patients transplanted at the Charite´Campus Benjamin Franklin or in the University Hospital of Mainz were collected at given time points. A total of 14 of these patients received thymoglobulin, 10 patients alemtuzumab and 10 patients no T-cell depletion. Patient characteristics and clinical data are summarized in Tables 1, 2 and 3 .
NK cell frequency in peripheral blood. NK cells numbers in PB at day þ 30 (median 350 per ml, range 20-1000) were comparable to values obtained from healthy donors (250, range 80-680). The NK cell count was not different between patients without T-cell depletion (250 per ml, range 20-1000) and patients receiving thymoglobulin as T-cell depletion (400 per ml, range 200-1000). The median NK cell count at day þ 30 of patients receiving alemtuzumab was reduced to 100 per ml (range 40-200; Po0.0005).
Anti-tumor reactivity of NK cells in the early phase after HSCT. At day þ 30 after HSCT, the percentage of degranulating NK cells toward tumor targets (median 2.3%) was reduced as compared to healthy individuals (median 5.4%; Po0.0005). The percentage of CD107a þ NK cells was not significantly different between patients without T-cell depletion (4.35%) and patients receiving thymoglobulin (2.75%), but was reduced to 0.85% when alemtuzumab was given as T-cell depletion (Po0.0005). The absolute number of tumor reactive (CD107a þ ) NK cells in PB was considerably reduced in patients receiving alemtuzumab as compared to patients receiving thymoglobulin (1.1 vs 13.0 per ml; P ¼ 0.02, Figure 3 ).
Influence of fludarabine and type of conditioning. In recipients of thymoglobulin as T-cell depletion, we performed a subgroup analysis comparing the NK cell count T-cell depletion influences NK cell function after HSCT O Penack et al and tumor reactivity of patients receiving fludarabine vs patients not receiving fludarabine, which was given prior to HSCT as a part of the conditioning regimen. The median NK cell counts (400 vs 400 per ml), percentages of tumor reactive NK cells (3.2 vs 2.5) and absolute numbers of tumor reactive NK cells (7.6 vs 11.1 per ml) were not significantly different in patients receiving fludarabine and patients without fludarabine, respectively. To exclude any significant impact of non-myeloablative conditioning (6 patients) vs myeloablative conditioning (28 patients) on the significance of our results, we performed a subgroup analysis of the NK cell activity including only the 28 patients receiving myeloablative conditioning and found similar results as compared to the analysis with all 34 patients: The median percentage of CD107a þ NK cells was 4.1, 2.9 and 0.85% in patients without T-cell depletion, patients receiving thymoglobulin and in patients receiving alemtuzumab, respectively (Po0.0005).
Engraftment. We found that 31 of 34 patients were complete donor chimeras at day þ 30 (490% in BM and PB). We failed to observe any significant impact of the type of T-cell depletion on overall leukocyte and platelet recovery in PB. Leukocyte numbers raised 41 per nl at day 14, 14 and 12 (median) in thymoglobulin, no T-cell depletion and alemtuzumab-treated patients, respectively. Platelet counts exceeded 20 per nl at day 11, 12 and 11 Abbreviations: Flu ¼ fludarabine; Mel ¼ melphalan; Treo ¼ treosulfan; Zev ¼ zevaline.
T-cell depletion influences NK cell function after HSCT O Penack et al
(median) in the thymoglobulin, no T-cell depletion and alemtuzumab group, respectively.
Discussion
NK cells are the predominant cells in the early phase after HSCT and there is strong evidence that the NK cellmediated GVT effects play a major clinical role. 2, 7, 14 Although thymoglobulin and alemtuzumab are increasingly used as in vivo T-cell depletion, their impact on the anti-tumor activity of NK cells has not been investigated yet.
In the present study, a novel flow cytometric method to detect the lytic granule membrane protein CD107a for determining NK cell degranulation enabled us easy and reliable assessment of NK cell activity in patients undergoing HSCT. Our data show that the frequency and antitumor activity of NK cells is profoundly reduced in patients receiving 100 mg alemtuzumab as compared to patients receiving 6 mg/kg thymoglobulin as T-cell depletion. Our findings can be explained by a slower in vivo clearance of alemtuzumab with prolonged effects on NK cells, which we found to be sensitive even to low concentrations of alemtuzumab (o1 mg/ml). Of note, all patients in our study received 100 mg alemtuzumab. We are not able to predict the NK cell activity in patients receiving lower dosages of alemtuzumab, which also might be sufficient to prevent GVHD in the HLA-matched setting.
In patients, receiving 90-100 mg alemtuzumab, the mean peak serum concentrations are in a range between 5 and 6.5 mg/ml. 15, 16 The mean peak serum concentrations of active rabbit ATG were 9.2 mg/ml (range 5.8 mg/ml) in patients receiving 6 mg/kg thymoglobulin. 17 Given these data, we found a similar toxicity of alemtuzumab and thymoglobulin in vitro. The profound difference between the antibodies seems to be the longer in vivo half-life of alemtuzumab (Campath-1H), which is a humanized antibody, under therapeutic conditions. Whereas the original rat Campath-1G had a short in vivo half-life of o1 day the terminal half-life of the now used Campath-1H (alemtuzumab) antibody was determined to be in a range between 15 and 21 days. 16 Transferred to our patients receiving 100 mg/ ml alemtuzumab, this means that at day þ 30, the expected serum concentrations would be around 1-2 mg/ml. Correlated to our in vitro results, where we found that NK cells were sensitive to concentrations of alemtuzumab as low as 0.1 mg/ml, it is understandable that the NK cell frequency and function was reduced considerably at day þ 30 post-HSCT in patients receiving alemtuzumab. In contrast, Table 3 Complications post-HSCT T-cell depletion/size of group Number of patients with GVHD Treatment of GVHD Number of patients with infections the active compound of thymoglobulin has a faster in vivo clearance. After administration of 6 mg/kg the half-life of active thymoglobulin was found to be 6 days. By a median of 15 days post-transplantation levels of active thymoglobulin were found to be o1 mg/ml. 17 Given these results, it can be explained by sub-therapeutic levels of active thymoglobulin at day þ 30 after HSCT that the NK cell activity was not significantly different in patients receiving 6 mg/kg thymoglobulin as compared to patients receiving no in vivo T-cell depletion.
The prolonged effects of alemtuzumab leading to reduced anti-tumor reactivity of NK cells might be an explanation for the recent reports of high rates of relapses after allogeneic HSCT when alemtuzumab was given as a part of the preparative regimen. 2 However, reduced antitumor reactivity caused by more extensive and prolonged T cell and dendritic cell depletion as an effect of alemtuzumab might also play an important role. The increased risk of infectious complications, especially viral infections, after application of alemtuzumab is another potential risk in the early phase after HCST. 18, 19 A possible limitation of our study is the fact that the donor source and the type of conditioning regimen were not equally distributed between the three groups of patients: 'no T-cell depletion', 'alemtuzumab' and 'thymoglobulin'. Although, it was found in previous studies investigating the NK cell reconstitution after HSCT that NK cell counts were independent from the stem cell source and from the conditioning regimen, we cannot completely exclude disturbing influences because our study was not randomized. [20] [21] [22] The distribution of patients receiving fludarabine between the two groups 'alemtuzumab' and 'thymoglobulin' was unequal. To exclude clinically relevant influences of fludarabine on the significance of our results, we performed a subgroup analysis in the thymoglobulin group comparing the NK cell count and tumor reactivity of patients receiving fludarabine vs patients not receiving fludarabine.
In conclusion, our data show a reduced frequency and anti-tumor activity of NK cells in the early phase post-HSCT in patients receiving in vivo T-cell depletion with alemtuzumab, but not in patients receiving thymoglobulin. Our findings can be explained by the long half-life of alemtuzumab under therapeutic conditions leading to prolonged immunosuppression and possibly increased risk of infectious complications and tumor relapse.
